secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001493152-25-021189
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close
--------------------------------------------------------------------------------

- Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.
- Received $3M cash at closing; additional $1M due upon availability of commercial product.
- Up to $6M in milestones: $3M each upon achieving $10M and $15M annual net sales of Xepi®.
- Company expects proceeds to fund operations to profitability, supporting Ameluz® PDT franchise.
- Transaction bolsters cash position after recent restructuring of agreement with Biofrontera AG.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/0001493152-25-021189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225021189/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer